In cell cultures analyzed in the current study, hrsACE2 inhibited the coronavirus load by a factor of 1,000-5,000. Credit: IMBA/Tibor Kulcsar
‘There is hope for this horrible pandemic,’ says UBC scientist Dr. Josef Penninger
An international team led by University of British Columbia researcher Dr. Josef Penninger has found a trial drug that effectively blocks the cellular door SARS-CoV-2 uses to infect its hosts.
The findings, published today in Cell, hold promise as a treatment capable of stopping early infection of the novel coronavirus that, as of April 2, has affected more than 981,000 people and claimed the lives of 50,000 people worldwide.
The study provides new insights into key aspects of SARS-CoV-2, the virus that causes COVID-19, and its interactions on a cellular level, as well as how the virus can infect blood vessels and kidneys.
“We are hopeful our results have implications for the development of a novel drug for the treatment of this unprecedented pandemic,” says Penninger, professor in UBC’s faculty of medicine, director of the Life Sciences Institute and the Canada 150 Research Chair in Functional Genetics at UBC.
“This work stems from an amazing collaboration among academic researchers and companies, including Dr. Ryan Conder’s gastrointestinal group at STEMCELL Technologies in Vancouver, Nuria Montserrat in Spain, Drs. Haibo Zhang and Art Slutsky from Toronto and especially Ali Mirazimi’s infectious biology team in Sweden, who have been working tirelessly day and night for weeks to better understand the pathology of this disease and to provide breakthrough therapeutic options.”
ACE2 — a protein on the surface of the cell membrane — is now at centre-stage in this outbreak as the key receptor for the spike glycoprotein of SARS-CoV-2. In earlier work, Penninger and colleagues at the University of Toronto and the Institute of Molecular Biology in Vienna first identified ACE2, and found that in living organisms, ACE2 is the key receptor for SARS, the viral respiratory illness recognized as a global threat in 2003. His laboratory also went on to link the protein to both cardiovascular disease and lung failure.
While the COVID-19 outbreak continues to spread around the globe, the absence of a clinically proven antiviral therapy or a treatment specifically targeting the critical SARS-CoV-2 receptor ACE2 on a molecular level has meant an empty arsenal for health care providers struggling to treat severe cases of COVID-19.
“Our new study provides very much needed direct evidence that a drug — called APN01 (human recombinant soluble angiotensin-converting enzyme 2 – hrsACE2) — soon to be tested in clinical trials by the European biotech company Apeiron Biologics, is useful as an antiviral therapy for COVID-19,” says Dr. Art Slutsky, a scientist at the Keenan Research Centre for Biomedical Science of St. Michael’s Hospital and professor at the University of Toronto who is a collaborator on the study.
In cell cultures analyzed in the current study, hrsACE2 inhibited the coronavirus load by a factor of 1,000-5,000. In engineered replicas of human blood vessel and kidneys — organoids grown from human stem cells — the researchers demonstrated that the virus can directly infect and duplicate itself in these tissues. This provides important information on the development of the disease and the fact that severe cases of COVID-19 present with multi-organ failure and evidence of cardiovascular damage. Clinical grade hrsACE2 also reduced the SARS-CoV-2 infection in these engineered human tissues.
“Using organoids allows us to test in a very agile way treatments that are already being used for other diseases, or that are close to being validated. In these moments in which time is short, human organoids save the time that we would spend to test a new drug in the human setting,” says Núria Montserrat, ICREA professor at the Institute for Bioengineering of Catalonia in Spain.
“The virus causing COVID-19 is a close sibling to the first SARS virus,” adds Penninger. “Our previous work has helped to rapidly identify ACE2 as the entry gate for SARS-CoV-2, which explains a lot about the disease. Now we know that a soluble form of ACE2 that catches the virus away, could be indeed a very rational therapy that specifically targets the gate the virus must take to infect us. There is hope for this horrible pandemic.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Blocking early stages of COVID-19
- COVID-19: 1 death, 12 cases in London-Middlesex as province enters 1st stage of reopening planon June 11, 2021 at 12:44 pm
Friday's update brings the region's pandemic case total to 12,412, of which 12,087 have resolved, an increase of 11 from the day before. At least 103 cases are active.
- Schedule these visits if you’ve been putting them off during COVID-19on June 10, 2021 at 11:14 am
During the early stages of the COVID-19 pandemic, you may have opted to avoid the doctor’s office altogether. You wouldn't be alone; 32 percent of adults in the United States avoided routine care ...
- Social media use one of four factors related to higher COVID-19 spread rates early onon June 9, 2021 at 2:04 pm
Researchers from York University and the University of British Columbia have found social media use to be one of the factors related to the spread of COVID-19 within dozens of countries during the ...
- Nanozymes to the rescue - potential role in fighting COVID-19on June 7, 2021 at 11:21 pm
Over the last few decades, researchers have developed artificial enzymes for many applications. Recently, they deployed nanomaterial-based enzyme mimetics or nanozymes in diagnosis and therapeutics.
- COVID-19 can cause long-term consequences for the kidneyson June 7, 2021 at 6:11 pm
The kidneys are a target organ of COVID-19 and are affected very early in the course. However, this is precisely where there is strong prognostic potential: As early as last spring, ...
Go deeper with Google Headlines on:
Blocking early stages of COVID-19
Go deeper with Bing News on:
- APEIRON Biologics Announces Changes to Management and Supervisory Boardson June 1, 2021 at 3:00 am
APN01 has three distinct potential clinical benefits for COVID-19 and has completed a double blind, placebo-controlled Phase 2 trial in Europe and Russia. Based on promising results, APN01 was ...
- One to Watch Companies - Research, Companies, mergers and acquisitions, Zymeworkson May 28, 2021 at 3:03 pm
Shares in US gene therapy company Avrobio closed 19% lower on Monday.
- One to Watch Companies - Research, LEO Pharma, Gene therapyon May 27, 2021 at 2:43 pm
Singapore-based clinical-stage biotech Hummingbird Bioscience today announced the close of its $125 million… Shares in US gene therapy company Avrobio closed 19% lower on Monday. USA-based LogicBio ...
- Apeiron plans COVID-19 trial of inhaled ACE2 formulationon May 25, 2021 at 12:40 am
Vienna-based Apeiron began studying APN01 in COVID-19 in the belief the soluble form of ACE2 may stop the coronavirus from entering human cells. The idea is that the molecule could serve as a ...
- Apeiron Biologics’ APN01 selected for large-scale US trial in Covid-19on May 20, 2021 at 5:40 pm
Apeiron Biologics AG announced the next development steps for APN01 (alunacedase alfa) for the treatment of Covid-19. Based on the recently announced clinical results from Apeiron’s phase 2 trial with ...